JP2024513227A5 - - Google Patents

Info

Publication number
JP2024513227A5
JP2024513227A5 JP2023561240A JP2023561240A JP2024513227A5 JP 2024513227 A5 JP2024513227 A5 JP 2024513227A5 JP 2023561240 A JP2023561240 A JP 2023561240A JP 2023561240 A JP2023561240 A JP 2023561240A JP 2024513227 A5 JP2024513227 A5 JP 2024513227A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutically acceptable
stereoisomer
prodrug
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023443 external-priority patent/WO2022216680A1/en
Publication of JP2024513227A publication Critical patent/JP2024513227A/ja
Publication of JP2024513227A5 publication Critical patent/JP2024513227A5/ja
Pending legal-status Critical Current

Links

JP2023561240A 2021-04-05 2022-04-05 Nek7阻害剤 Pending JP2024513227A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163170708P 2021-04-05 2021-04-05
US63/170,708 2021-04-05
US202163185282P 2021-05-06 2021-05-06
US63/185,282 2021-05-06
PCT/US2022/023443 WO2022216680A1 (en) 2021-04-05 2022-04-05 Nek7 inhibitors

Publications (2)

Publication Number Publication Date
JP2024513227A JP2024513227A (ja) 2024-03-22
JP2024513227A5 true JP2024513227A5 (cg-RX-API-DMAC7.html) 2025-04-10

Family

ID=81448482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561240A Pending JP2024513227A (ja) 2021-04-05 2022-04-05 Nek7阻害剤

Country Status (11)

Country Link
EP (1) EP4320127A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024513227A (cg-RX-API-DMAC7.html)
KR (1) KR20230175222A (cg-RX-API-DMAC7.html)
AU (1) AU2022255486A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019435A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214042A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023014204A2 (cg-RX-API-DMAC7.html)
IL (1) IL307258A (cg-RX-API-DMAC7.html)
MX (1) MX2023011464A (cg-RX-API-DMAC7.html)
PH (1) PH12023552774A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022216680A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
WO2024059200A1 (en) * 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors
EP4671246A1 (en) * 2023-02-24 2025-12-31 Japan Tobacco Inc. COMPOSITE OF 6-ALCOXYPYRAZOLOPYRIMIDINE AND ITS PHARMACEUTICAL USE
TW202448887A (zh) * 2023-02-24 2024-12-16 日商日本煙草產業股份有限公司 取代吡唑并嘧啶化合物及其醫藥用途
AU2024240240A1 (en) * 2023-03-17 2025-09-25 Ventus Therapeutics U.S., Inc. Urea derivatives for inhibiting nlrp3 and uses thereof
WO2025067411A1 (zh) * 2023-09-28 2025-04-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
CN122535593A (zh) * 2023-12-29 2026-08-07 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途
WO2026064385A1 (en) * 2024-09-18 2026-03-26 Ventus Therapeutics U.S., Inc. Oxadiazolone inhibitors of nlrp3 and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
ATE446962T1 (de) 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten
CN101558068A (zh) 2006-10-16 2009-10-14 诺瓦提斯公司 用作蛋白激酶抑制剂的苯乙酰胺类
JP2010531887A (ja) 2007-06-26 2010-09-30 グラクソスミスクライン エルエルシー ベンズイミダゾールチオフェンの調製方法
US8980899B2 (en) * 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
US9321763B2 (en) 2012-04-04 2016-04-26 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
CN103421005A (zh) 2012-05-16 2013-12-04 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
CN105431436B (zh) 2013-05-14 2017-11-28 内尔维阿诺医学科学有限公司 吡咯并[2,3‑d]嘧啶衍生物,它们的制备方法和它们作为激酶抑制剂的用途
WO2014206343A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
EP3102195B1 (en) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
WO2016029776A1 (en) 2014-08-26 2016-03-03 Astar Biotech Llc Protein kinase inhibitors
CN105837575B (zh) 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
MX376201B (es) 2015-12-30 2025-03-07 Nqp 1598 Ltd Compuestos inhibidores de metaloenzima.
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
ES2921257T3 (es) 2016-06-20 2022-08-22 Daegu Gyeongbuk Medical Innovation Found Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer
KR102500416B1 (ko) 2016-06-21 2023-02-17 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서의 n-(치환된-페닐)-설폰아미드 유도체
EP3296297A1 (en) 2016-09-15 2018-03-21 Centre National De La Recherche Scientifique Benzimidazol derivatives for treating filovirus infection
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
WO2018215668A1 (en) 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
WO2018222917A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
EP3774797B1 (en) * 2018-04-05 2025-11-19 Merck Patent GmbH Heteroaryl compounds as type ii irak inhibitors and uses hereof
EP3778590A4 (en) 2018-04-09 2021-12-22 ShanghaiTech University ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
WO2019200120A1 (en) 2018-04-11 2019-10-17 Lycera Corporation Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions
TWI848954B (zh) 2018-06-13 2024-07-21 英屬開曼群島商百濟神州有限公司 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
CN111377907B (zh) 2018-12-26 2023-03-28 杭州百新生物医药科技有限公司 一种多取代苯氨基嘧啶衍生物及其制备方法和用途
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
WO2020206583A1 (en) 2019-04-08 2020-10-15 Qilu Regor Therapeutics Inc. Kinase inhibitors and uses thereof
KR20220066290A (ko) * 2019-08-29 2022-05-24 히버셀, 인크. Perk 억제 피롤로피리미딘 화합물
CN112552302B (zh) * 2019-09-26 2022-05-13 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
CN114761000A (zh) 2019-10-01 2022-07-15 金翅雀生物公司 Cdk5的取代的1,6-萘啶抑制剂
JP7461605B2 (ja) 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
US20230210853A1 (en) 2020-05-08 2023-07-06 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
CN113717156B (zh) 2020-05-25 2023-05-09 南京红云生物科技有限公司 Egfr抑制剂、其制备方法及用途
GB202010464D0 (en) 2020-07-08 2020-08-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Similar Documents

Publication Publication Date Title
US12312349B2 (en) Apoptosis-inducing agents
EP2890375B1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2021193897A1 (ja) 置換ピリダジン化合物
JP4881725B2 (ja) Tie−2モジュレータと使用方法
JP6499077B2 (ja) アルツハイマー病と関連疾患の治療のための併用療法
JP2023030076A (ja) Fxrアゴニストの固体形態
JP2022505525A5 (cg-RX-API-DMAC7.html)
JP6602902B2 (ja) 脾臓チロシンキナーゼi(syk)阻害剤としての2−(2−アミノシクロヘキシル)アミノピリミジン−5−カルボキサミド類
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
AU2014340182A1 (en) Cromolyn derivatives and related methods of imaging and treatment
RU2005128190A (ru) Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации
JP2008520742A5 (cg-RX-API-DMAC7.html)
CA2679198A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
IL217195A (en) Forazanobenzazimidazoles, Methods for their Preparation and Uses
KR20240004634A (ko) 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도
CN1265098A (zh) 抑制因子xa的杂环衍生物
JP7708760B2 (ja) 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用
CN103113386B (zh) 氮杂环取代二氢青蒿素衍生物及其应用
CN115003658B (zh) 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途
WO2022037648A1 (zh) 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
JP2021510168A5 (cg-RX-API-DMAC7.html)
JP2023506496A (ja) 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用
JP2023505587A (ja) 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用
JP7854001B2 (ja) α1-アンチトリプシン欠乏症の処置のための組成物およびそれらの使用
WO2023038815A1 (en) Irak inhibitor for treating cytokine release-related conditions associated with infection by a respiratory virus